Examining the Therapeutic Potential of CRISPR-Cas9 Gene Editing in Spondyloarthritis: Efficacy of TNF Inhibitor Adalimumab

Research Article

Abstract

Spondyloarthritis (SpA) encompasses a group of inflammatory rheumatic diseases characterized by axial and peripheral joint involvement, enthesitis, and extra-articular manifestations. Despite advancements in understanding the genetic and immunological underpinnings of SpA, current therapeutic options, including biologic therapies such as the TNF inhibitor adalimumab, primarily focus on symptom management and often show variable efficacy among patients. The advent of CRISPR-Cas9 gene editing technology presents a revolutionary opportunity to directly modify genetic contributors to SpA, potentially transforming the therapeutic landscape and enhancing the efficacy of adalimumab. This review investigates the feasibility and implications of utilizing CRISPR-Cas9 for targeted gene editing in SpA to improve patient response to adalimumab. We review the current knowledge on genetic mutations and polymorphisms associated with SpA pathogenesis, focusing on key genes involved in immune regulation and inflammatory pathways targeted by adalimumab. By leveraging CRISPR-Cas9, we aim to explore how precise genetic modifications can optimize the molecular targets of adalimumab, thereby enhancing its efficacy and reducing refractory cases. Preliminary studies in animal models and cell cultures demonstrate promising results, showcasing the potential of CRISPR-Cas9 to correct genetic abnormalities and synergize with adalimumab to restore normal cellular functions and reduce inflammation. However, translating these findings into clinical applications requires addressing significant challenges, including delivery methods, off-target effects, and long-term safety. Future research directions include optimizing CRISPR-Cas9 delivery systems, such as viral vectors and nanoparticle-based approaches, to enhance specificity and efficiency in conjunction with adalimumab. Additionally, comprehensive preclinical studies and early-phase clinical trials are essential to evaluate the combined therapeutic potential and safety profile of CRISPR-Cas9 and adalimumab in human subjects with SpA. This pioneering approach not only holds the promise of groundbreaking treatments for SpA but also sets the stage for broader applications of gene editing in rheumatology. By targeting the genetic roots of rheumatic diseases and optimizing adalimumab interactions, CRISPR-Cas9 could offer a new era of precision medicine, offering more effective and durable therapeutic outcomes.